Report Phase 3 results for fianlimab plus cemiplimab versus pembrolizumab in first-line metastatic melanoma
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Apr 2026
- Due
- 30 Jun 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company remains on track to report results from the Phase 3 study of fianlimab in combination with cemiplimab versus pembrolizumab in first-line metastatic melanoma in the second quarter of 2026.”
What we found
Evidence strength A What the grades mean
Regeneron announced Phase 3 fianlimab results in May 2026, within Q2 2026, though the primary endpoint did not reach statistical significance versus pembrolizumab.
-
A Regeneron Pharmaceuticals 8-K filed 2026-07-30
“In May 2026, the Company announced results from the Phase 3 trial evaluating two dose levels of fianlimab in combination with cemiplimab as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma.” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2026-07-30
“in May 2026, we announced that a Phase 3 trial evaluating fianlimab in combination with Libtayo in first-line metastatic melanoma did not reach statistical significance for its primary endpoint compared to pembrolizumab monotherapy.” ✓ confirmed on the page
Market reaction: the shares moved +5.3% against the S&P 500 over the three sessions around the disclosure (29 Jul 2026 to 3 Aug 2026). What this measures
Checked 11 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 fianlimab results in first-line metastatic melanoma
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-REGN-006358 · Corrections policy